TY - JOUR
T1 - Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome
AU - Petrich, Adam
AU - Kahl, Brad
AU - Bailey, Howard
AU - Kim, Kyungmann
AU - Turman, Nancy
AU - Juckett, Mark
PY - 2008/1
Y1 - 2008/1
N2 - We conducted a phase II trial of doxercalciferol, a vitamin D2 analogue, in 15 patients with MDS. Each received doxercalciferol 12.5μg orally daily for 12 weeks. Nine of 15 patients completed the prescribed course and of these, six had stable disease. No patient had a response (IWG criteria) and overall eight patients experienced progressive disease while on therapy. Two patients with chronic myelomonocytic leukemia (CMML) had a marked rise in monocytes on study. Overall the treatment was well tolerated. One patient was removed from study due to hypercalcemia. We conclude that short-term treatment with doxercalciferol has limited activity in patients with MDS.
AB - We conducted a phase II trial of doxercalciferol, a vitamin D2 analogue, in 15 patients with MDS. Each received doxercalciferol 12.5μg orally daily for 12 weeks. Nine of 15 patients completed the prescribed course and of these, six had stable disease. No patient had a response (IWG criteria) and overall eight patients experienced progressive disease while on therapy. Two patients with chronic myelomonocytic leukemia (CMML) had a marked rise in monocytes on study. Overall the treatment was well tolerated. One patient was removed from study due to hypercalcemia. We conclude that short-term treatment with doxercalciferol has limited activity in patients with MDS.
KW - Doxercalciferol
KW - Myelodysplastic syndrome
KW - Phase II study
UR - http://www.scopus.com/inward/record.url?scp=38549145862&partnerID=8YFLogxK
U2 - 10.1080/10428190701713648
DO - 10.1080/10428190701713648
M3 - Article
C2 - 18203012
AN - SCOPUS:38549145862
SN - 1042-8194
VL - 49
SP - 57
EP - 61
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 1
ER -